Comment from Bean Thomas

I respectfully ask the FDA to support the inclusion of these seven peptides on the 503A Bulks List so that licensed 503A compounding pharmacies can continue to prepare patient-specific prescriptions under the care of qualified healthcare providers. As someone who has personally benefited from medically supervised peptide therapy, I have experienced firsthand how meaningful these treatments can be. I initially sought treatment to improve my overall health and address an old knee injury that had gradually limited my mobility. Climbing stairs had become painful, and I had simply accepted that it was something I would have to live with. Under the supervision of a licensed medical provider, peptide therapy became one tool in my overall health plan. It was never presented as a shortcut or a cure. It was part of a comprehensive approach that also included making healthier lifestyle choices and staying active. Since beginning treatment, I have lost 10 pounds and, more importantly, my knee has improved to the point that I can walk up stairs again without the pain that had become part of my daily life. That improvement has allowed me to be more active, exercise more consistently, and continue building healthier habits. These therapies are about much more than weight loss. Many patients rely on compounded peptides because there are no commercially available alternatives that meet their specific medical needs, or because individualized dosing is necessary. Removing access would not eliminate the need for treatment. It would simply reduce safe, physician-supervised options for patients who have benefited from personalized care. Please consider the real experiences of patients whose quality of life has improved through responsible access to compounded peptide therapies. Preserving access through qualified 503A compounding pharmacies allows healthcare providers to continue making individualized treatment decisions based on each patient’s unique needs.